Prasun J. Mishra M.Sc., PhD

Scientific governing committee member

Dr. Mishra discovered the role for noncoding RNA in drug resistance and pharmacogenomics. His laboratory at Genentech is primarily focused on developing ‘lifesaving’ next-generation personalized anti-cancer drugs. Mishra lab has been recognized globally by numerous awards and honors, including prestigious NIH Earl Stadtman Lectureships, Thompson Reuters Lectureship and NCI Director’s Innovation Awards. Discoveries lead by Dr. Mishra and his teams have contributed to the development of new and viable strategies of prevention, diagnosis and treatment of cancer patients in the clinic. He earned his PhD degree in Pharmacology from Rutgers University, NJ and a postdoctoral fellowship from National Institutes of Health (NIH), Bethesda, MD. Before moving to Genentech he served as a principal investigator at National Cancer Institute (NCI), National Institutes of Health (NIH) on two peer-reviewed NCI/NIH-funded grants focused on developing improved anti-cancer therapy. Dr. Mishra has also served as a non-dilutive funding adviser to accelerate commercialization and helped organizations to compete for over $30 billion available funds in non-dilutive federal R&D funding. He also serves on the advisory board of California Life Sciences Association (CLSA), the leading voice for California’s life sciences sector to help grow California’s life sciences innovation ecosystem. Moreover, his passion for translational research has resulted in over 100 presentations/publications including 5 US patents, 5 federal technology transfer awards and 7 drugs/drug combinations in clinical trials.